NEW DELHI: In a time when big players like Reliance Industries (RIL), both Amazon and the Tata Group are eyeing a share of India’s flourishing e-pharmacy marketplace, Mumbai-headquartered PharmEasy on Tuesday gained smaller rival Medlife which makes it the biggest payoff in the area. PharmEasy, valued at $1.5 billion, became India’s first e-pharmacy unicorn a month later increasing around $320 million in TPG Growth and Prosus Ventures. The deal will end from Medlife stopping operations and present clients having the ability to get their information through PharmEasy program. Dhaval Shah, co-founder in PharmEasy, stated in a LinkedIn article the purchase is likely to create the combined entity the biggest health care delivery platform throughout the nation with a space. “Moving ahead, we plan to provide far better support to the individuals,” he explained. While the merged entity will serve 2 million clients each month, Bengaluruheadquartered Medlife’s retail partners will soon be on-boarding Phar mEasy. “The acquisitions represent the developing tendency to fortify existence in the internet health marketplace,” said Raja Lahiri, partner at Grant Thornton Bharat. India’s e-health marketplace, which can be set to turn into a 16-billion chance by FY25, has witnessed a flurry of action. RIL gained 65 percent in drugstore startup Netmeds for Rs 620 crore, although Amazon had established its pharmacy perpendicular to deliver medications to customers throughout the nation. The Tata Group, also, has demonstrated a strong interest in New Delhi-headquartered e-pharmacy 1mg.